

Karolinska Development AGM 2017 / Information on candidates nominated for election or re-election to the board

Re election

Tse Ping

Vice Chairman and Board member since 2015. Other appointments Founder and Chairman of Sino Biopharmaceutical Limited, Senior Vice Chairman of Charoen Pokphand Group, where he has extensive experience of major merger and acquisition activity including Ping An Insurance, CITIC Group, China Mobile, ITOCHU Corporation, and Marko Group. Previous appointments include Member of the Ninth, Tenth, and Eleventh National Committee of the Chinese People's Political Consultative Conference. Independent of the company, its executive management and in relation to the company's major shareholders. Holdings in Karolinska Development 4,853,141 shares and SEK 272,858,294 in convertible bonds (by related legal person).

Niclas Adler

Board member since 2015. Born 1971. PhD, MSc. Other appointments Managing Partner Accelerated Innovation Ltd, Chairman Akinion Pharmaceuticals AB, ITH Immune Therapy Holdings AB, ADD Accelerated Drug Development AB and NGT Partners, member of the Board of Directors of AO Holding AB and SCI Innovation AB. Previous appointments include President IPMI International Business School, Jakarta, Director Truepoint Partners, Boston, Fellow, Sunningdale Institute, London, Fellow, Centre For International Business and Management, Judge Business School, Cambridge University, CEO Jönköping International Business School, Director FENIX Center for Innovations in Management, Stockholm School of Economics, Executive Director, Stockholm School of Entrepreneurship. Independent of the company, its executive management and in relation to the company's major shareholders. No holdings in Karolinska Development.

Vlad Artamonov

Board member since 2012. Born 1978. MBA, B.Sc. Other appointments include Board member and Partner of Coastal Capital International Ltd. Previous appointments include Board Member of Redbank Energy Ltd., Investment Analyst at Greenlight Capital Inc., position in the Global Merger & Acquisition Group at Merrill Lynch in New York. Independent of the company, its executive management and in relation to the company's major shareholders. Holdings in Karolinska Development 3,470,541 shares of series B (via related legal person).

Hans Wigzell

Board member since 2006. Born 1938. Professor Emeritus of Immunology and MD. Other appointments include Chairman of Rhenman & Partner Asset Management AB and Cadila Pharmaceuticals Sweden Aktiebolag, Board member of Sarepta Therapeutics Inc. and RaySearch Laboratories AB. Member of The Royal Swedish Academy of Engineering Sciences and of the Royal Swedish Academy of Sciences. Previous assignments include, among others, the President of Karolinska Institutet's Nobel Committee, and President of Karolinska Institutet and Director General of Smittskyddsinstitutet. Independent of the company, its executive management and in relation to the company's major shareholders. Holdings in Karolinska Development 8,491 shares of series B and SEK 39,992 convertible loan per end 2016.

New election

Hans-Olov Olsson

Born 1941. Econ Dr h.c., Other assignments; Senior Advisor Geely Group, IVA Member, Board member Konungens stiftelse för ungt ledarskap Earlier assignments; Senior industrial advisor Rotschild&Co, Chairman Volvo Cars, Vice-Chairman Volvo Cars, Senior vice president, Ford Motor Company, CEO Volvo Cars, Chairman Chalmers University of Technology, Chairman Association of Swedish Engineering Industries, Vice-Chairman Confederation of Swedish Enterprises, Board member Elanders, SKF, Lindab, Vattenfall and Höganäs. Independent of the company, its executive management and in relation to the company's major shareholders. No holdings in Karolinska Development.

Anders Härfstrand

Born 1956. MD, PhD. Other assignments; Chairman of Härfstrand Consulting, Board member Prothema Plc, Senior Commercial Advisor HBM Partners, Earlier assignments; Chief Executive Officer of BBB Therapeutics BV, President and Chief Executive Officer Europe of Makhteshim Agan Industries Ltd; President and Chief Executive Officer of Humabs BioMed SA; Chief Executive Officer of Nittec Pharma AG, Various executive and management roles at Serono, Pfizer and Pharmacia. Independent of the company, its executive management and in relation to the company's major shareholders. No holdings in Karolinska Development.

Magnus Persson

Born 1960. MD PhD Assoc Prof. Educated at Karolinska Institutet. Previous assignments CEO Karolinska Institutet Holding AB, Managing Partner The Column Group, Partner HealthCap, Clinical Research Physician Sanofi. Current board assignments include Galecto Biotech AS (Chairman), SLS Invest AB (Chairman) Health Innovation Platform AB (Chairman), Cantargia AB (Chairman), Initiator Pharma (Chairman), Albumedix AS, Immunicum AB and Medical Prognosis Institute AS. No holdings in Karolinska Development.